Patent ID: 11965176
Assignee: HUNAN SIWEIKANG THERAPEUTICS CO. LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC C

Claim 14:
15. A method of producing a population of immune cells with reduced inflammatory properties, the method comprising:
(i) providing a population of immune cells; and
(ii) modifying the population of immune cells to:
(a) reduce production of one or more inflammatory proteins selected from the group consisting of GM-CSF, IL2, TNF, or a combination thereof as compared with wild-type immune cells of the same type under the same conditions; and
(b) express one or more antagonists of the one or more inflammatory proteins and/or express one or more immune suppressive cytokines,

wherein (ii) comprises introducing into the population of immune cells one or more nucleic acids coding for one or more antagonists of the one or more inflammatory proteins and/or one or more immune suppressive cytokines,
wherein the one or more antagonists in (b) comprise IL-1RA or an antibody selected from the group consisting of tocilizumab, sirukumab, sarilumab, siltuximab, olokizumab, clazakizumab, or an antigen-binding fragment thereof, or a combination thereof,
wherein the one or more immune suppressive cytokines in (b) comprise TGFβ, IL-4, IL-10, IL-13, IL-33, IL-35, or IL-37, wherein the population of modified immune cells comprises T cells, and
wherein the one or more nucleic acids are in operable linkage to a promoter(s) for expression of the one or more antagonists and/or the one or more immune suppressive cytokines in the immune cells.